Jessica Hergert

Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com

Articles

Embracing the Challenge and the Grind: Paul G. Richardson is a Giant of Cancer Care in Myeloma

March 23rd 2022

Paul G. Richardson, MD, started his journey in medicine delivering tea and biscuits to patients and ended up making seminal advances in myeloma care.

Shifting Treatment Sequencing Patterns and New Approaches Transform Breast Cancer Paradigm

February 14th 2022

Jennifer M. Matro, MD provides an in-depth look at clinical trials that have added to the breast cancer paradigm and how she is interpreting the findings for clinical practice.

Nuanced Decision-Making Strategies Are Needed as the Multiple Myeloma Paradigm Grows

February 11th 2022

Saad Z. Usmani, MD, MBA, FACP, shares key takeaways from presentations given during the meeting on the evolving paradigms of frontline, early relapsed, and late relapsed multiple myeloma, the current role of bispecific antibodies and CAR T-cell therapy, and emerging immunotherapies and also trials in progress in the space.

Expanded Combinations, Novel Agents, and MRD-Informed Trials Transform Myeloma Paradigm

February 11th 2022

Laura Finn, MD, provides a deep dive into pivotal data with combinations and novel agents that have changed the paradigm for patients with newly diagnosed, early relapsed, and late relapsed multiple myeloma.

Advances Improve Outcomes but Leave Space for Curative Strategies in Metastatic Breast Cancer

February 11th 2022

John T. Cole, MD, discusses how updates in HER2-positive breast cancer have affected sequencing strategies, selecting between CDK4/6 inhibitors in the adjuvant and metastatic settings of hormone receptor HR–positive breast cancer, and the need for additional therapies in triple-negative breast cancer.

Multiple Myeloma Landscape Grows At Rapid Pace With Quadruplets and BCMA-Directed Therapy

February 10th 2022

Douglas W. Sborov, MD, MS, discusses key data and therapeutic developments that have reshaped the treatment of patients with newly diagnosed and relapsed/refractory multiple myeloma.

Personalized Medicine Approaches Continue to Gain Steam in BRAF/NRAS+ Metastatic Melanoma

February 9th 2022

Meredith McKean, MD, MPH, discusses how the presence of atypical BRAF mutations affects treatment selection in patients with metastatic melanoma, highlighted the ongoing KN-8701 trial, and explained why developments in this space further solidify the importance of broad molecular profiling.

Brachytherapy Represents a Potential Strategy in AYA Patients With Rhabdomyosarcoma

February 9th 2022

Although brachytherapy is rarely utilized as a treatment for pediatric and adolescent/young adult patients in the United States, AYA patients with rhabdomyosarcoma treated with BT had favorable survival outcomes.

Investigators Set Sights Beyond the PACIFIC Regimen in Unresectable Stage III NSCLC

February 7th 2022

Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.

Upifitamab Rilsodotin Under Investigation in Several Trials to Bridge Unmet Need in Recurrent Ovarian Cancer

February 4th 2022

Debra L. Richardson, MD, FACS, FACOG, discusses the role of NaPi2b as a target for upifitamab rilsodotin, data that have emerged from the ongoing phase 1/2 UPLIFT trial, and the development of other studies like UPNEXT and UPGRADE that are further evaluating upifitamab rilsodotin in patients with ovarian cancer.

RNA-Based NGS Offers the Potential to Identify More Patients With Rare Alterations in NSCLC

February 4th 2022

The field of non–small cell lung cancer has exploded with continuous advances in targeted therapies directed toward key molecular alterations, including rare mutations like MET exon 14 skipping mutations, RET rearrangements, and ROS1 mutations.

Investigation Into the Actionability of Atypical BRAF Mutations Continues in Solid Tumors

February 3rd 2022

Developing BRAF inhibitors for patients with atypical class II and III mutations has become an exciting area of research.

Established Agents in Metastatic HER2+ Breast Cancer Become the Focus of Research in Earlier-Stage Disease

February 2nd 2022

Laura Spring, MD, discusses the influence of the findings from the DESTINY-Breast03 trial with trastuzumab deruxtecan on practice patterns in HER2-positive breast cancer, updates in the management of brain metastases, and ongoing clinical trials she is keeping an eye on to move therapies into earlier lines of treatment.

Sequencing Strategies Shift in Metastatic HER2+ Breast Cancer

February 1st 2022

Ruta D. Rao, MD, discusses factors that inform treatment selection for patients with metastatic HER2-positive breast cancer, the effects key data that emerged in 2021 have had on sequencing, strategies to mitigate toxicities associated with trastuzumab deruxtecan, and remaining questions regarding sequencing that may be the focus of ongoing research effort.

Immunotherapy Approvals Signal a Need for Molecular Testing in Endometrial Cancer

January 31st 2022

Sarah Lee, MD, MBA, discusses the use of checkpoint inhibitors in endometrial cancer, research regarding the association between MSI-H, dMMR, and TMB-H disease, and the importance of broad molecular testing to ensure all eligible patients are appropriately matched to immunotherapeutic options.

Breast Cancer Paradigm Pushes Forward With Novel Agents, Sequencing Strategies, and Dynamic Biomarkers

January 29th 2022

Aditya Bardia, MD, MPH, discusses key updates in HER2-positive, hormone receptor–positive, and triple-negative breast cancers, as well as the evolving clinical application of gene signature assays, liquid biopsies, and genotyping.

Trastuzumab Deruxtecan Stands Out for HER2+ and HER2-Low Breast Cancer

January 25th 2022

Aditya Bardia, MD, MPH, discusses the clinical implications of the DESTINY-Breast03 trial, the encouraging data from the DAISY trial, and sequencing questions that remain in the evolving paradigm of HER2-positive breast cancer.

NCCN Guidelines Include Neratinib-Based Recommendations for HER2+ Breast Cancer

January 24th 2022

The National Comprehensive Cancer Network guidelines were updated for 2022 regarding the treatment of patients with breast cancer to include 2 new recommendations involving neratinib.

Nivolumab/Ipilimumab Showcases Prolonged Treatment-Free Survival in Advanced RCC

January 24th 2022

Over a 42-month period, the combination of nivolumab and ipilimumab induced a longer treatment-free survival compared with sunitinib (Sutent) when used as frontline therapy in patients with advanced renal cell carcinoma.

Durvalumab Plus Chemotherapy Improves Survival in Advanced Biliary Tract Cancer

January 18th 2022

Treatment with the PD-L1 inhibitor durvalumab in combination with gemcitabine and cisplatin resulted in significantly improved overall survival vs placebo plus chemotherapy in patients with advanced biliary tract cancer.